hero section gradient
12 handpicked stocks

Popular Dividend Stocks

Invest in well-known companies that not only offer growth potential but also pay you a regular income. These household names have strong track records of sharing profits with their shareholders through dividends.

Author avatar

Han Tan | Market Analyst

Published on May 24

Your Basket's Financial Footprint

Market capitalisation breakdown for 'Popular Dividend Stocks' basket and key investor takeaways.

Key Takeaways for Investors:
  • Large-cap concentration likely reduces volatility and tends to track broad market moves, offering relatively lower risk.
  • Suitable as a core holding in a diversified portfolio, not as a speculative or short-term trade.
  • Expect steady long-term appreciation rather than explosive short-term gains; income and stability are the focus.
Total Market Cap
  • AAPL: $3.90T

  • MSFT: $3.85T

  • KO: $306.39B

  • Other

About This Group of Stocks

1

Our Expert Thinking

These stocks combine name recognition with dividend income potential. We've selected established companies across different sectors that have demonstrated commitment to paying shareholders a portion of their profits regularly, giving you both potential growth and ongoing income.

2

What You Need to Know

Dividends are regular payments companies make to shareholders from their profits. These stocks come from various industries including technology, food and beverage, energy, and financial services, allowing you to diversify your income sources while investing in familiar brands.

3

Why These Stocks

Each company in this collection has a history of dividend payments, making them attractive for income-focused investors. We've handpicked well-established brands that not only offer name recognition but have demonstrated a commitment to sharing profits with their shareholders.

Why You'll Want to Watch These Stocks

💰

Get Paid While You Wait

These companies pay you regular dividends just for being a shareholder. You'll earn income even when stock prices aren't moving up.

🌟

Household Names You Already Trust

From the coffee you drink (Starbucks) to the technology you use (Apple, Microsoft), these are brands you interact with daily and can now own a piece of.

🛡️

Built for Uncertain Times

Dividend-paying companies tend to be more stable during market downturns. Many of these stocks have histories of maintaining or increasing their dividends even through tough economic periods.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

🚀

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Global Infrastructure Partners: UAE Exposure Risks

Global Infrastructure Partners: UAE Exposure Risks

The UAE's strategic push for economic diversification and smart city development is creating significant demand for advanced construction and infrastructure solutions. This basket provides exposure to a selection of US and EU-listed companies that supply essential materials, technology, and engineering services to the region's projects.

UAE Infrastructure Global Suppliers Breakdown

UAE Infrastructure Global Suppliers Breakdown

As the UAE continues its ambitious economic diversification, demand for world-class infrastructure creates opportunities for the companies that build it. This basket offers exposure to US and EU-listed industrial, materials, and technology firms that are integral to developing these large-scale projects.

Antiviral M&A Wave: Biotech Opportunities in 2025

Antiviral M&A Wave: Biotech Opportunities in 2025

Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.

Frequently Asked Questions